Beata M. M.
- Country
- Poland
- Department
- Oddział Onkologii Ginekologicznej
Research Overview
- Efficacy and Safety of Inavolisib plus Combination Therapy in Patients with Endocrine-Resistant HR+/HER2- Advanced Breast Cancer with Chromosome 8p Loss
- Phase 3 Randomized Study of Rinatabart Sesutecan + Bevacizumab vs Bevacizumab in Recurrent Platinum‑Sensitive Ovarian Cancer after Second‑Line Platinum Doublet
- Phase 3 Randomized Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in HR+/HER2- Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 217 of 456 partner sites.
Specializations
Breast Cancer
Focuses on hormone receptor‑positive, HER2‑negative breast cancer across early and metastatic stages. Also addresses triple‑negative breast cancer in neoadjuvant and advanced settings.
- Neoadjuvant endocrine therapy
- CDK4/6 inhibitor combinations
- Antibody‑drug conjugates in metastatic disease
- Adjuvant immunotherapy trials
The investigator contributes to therapeutic strategies that integrate targeted agents and immunotherapy for breast cancer.
Gynecologic Oncology
Investigates malignancies of the uterus, ovary, fallopian tube and cervix, emphasizing advanced endometrial cancer. Research also targets high‑grade serous ovarian cancer and locally advanced cervical cancer.
- PARP inhibitor maintenance
- HER2‑targeted therapy in endometrial cancer
- Immune checkpoint blockade in cervical cancer
- Combination chemotherapy with anti‑angiogenic agents
Research aims to improve outcomes for patients with gynecologic tumors through precision medicine approaches.
Non‑Small Cell Lung Cancer
Concentrates on advanced and metastatic NSCLC including PD‑L1‑positive disease. Also explores tumors with actionable genomic alterations such as KRAS/NRAS/BRAF wild‑type disease.
- Immunotherapy with checkpoint inhibitors
- Targeted therapy for KRAS/NRAS/BRAF wild‑type disease
- Combination regimens with chemotherapy
- Neoadjuvant strategies for resectable stage III disease
Efforts target durable control of lung cancer using modern systemic options.
Urothelial and Bladder Cancer
Addresses muscle‑invasive bladder cancer and advanced urothelial carcinoma. Focuses on integrating checkpoint inhibition with standard chemotherapy.
- Durvalumab‑based regimens
- Tremelimumab in combination therapy
- Adjuvant immunotherapy after chemoradiation
- Biomarker‑driven patient selection
The work seeks to expand effective immunologic treatments for urothelial malignancies.
Gastrointestinal and Colorectal Cancer
Explores malignancies of the stomach, gastro‑esophageal junction and colon, with attention to HER2‑positive gastric adenocarcinoma. Also investigates KRKR/NRAS/BRAF wild‑type colorectal disease and associated therapeutic options.
- HER2‑targeted therapy in gastric adenocarcinoma
- Anti‑angiogenic agents in colorectal cancer
- Immunotherapy for microsatellite stable disease
- Combination strategies with chemotherapy
Research integrates targeted and immune approaches to improve survival in GI cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.